Related Experiment Videos

Novel biomarkers for heart failure

Navaid Iqbal1, Khwaja Sami Alim, Hermineh Aramin

  • 1Veterans Affairs San Diego Healthcare System, San Diego, CA, USA.

Expert Review of Cardiovascular Therapy
|August 29, 2013
PubMed

Insights

New biomarkers offer improved heart failure (HF) diagnosis and risk assessment. This review explores cutting-edge biomarkers beyond established ones like NT-proBNP for better HF management.

Area of Science:

  • Cardiology
  • Biomarker Research
  • Internal Medicine

Background:

  • Heart failure (HF) presents a significant health system burden due to rising prevalence and costs.
  • Effective HF management requires earlier diagnosis, precise risk stratification, and cost-effective treatments to reduce hospitalizations.
  • Current diagnostic and management strategies for HF are evolving, particularly in acute settings.

Purpose of the Study:

  • To review novel biomarkers for heart failure (HF) diagnosis and management.
  • To highlight biomarkers beyond established markers like NT-proBNP.
  • To provide insight into cutting-edge biomarkers for improved HF patient care.

Main Methods:

  • Literature review of recent research on HF biomarkers.
  • Analysis of established biomarkers (e.g., NT-proBNP) and their limitations.
  • Identification and discussion of emerging biomarkers (e.g., troponins, GDF-15, ST-2, Galectin-3).

Main Results:

  • Established biomarkers like NT-proBNP are clinically useful but have limitations.
  • Numerous novel biomarkers show promise for HF diagnosis and risk stratification.
  • A multi-marker approach is essential for adequate HF patient risk assessment.

Conclusions:

  • Novel biomarkers are crucial for advancing the diagnosis and management of heart failure.
  • Emerging biomarkers offer enhanced capabilities for risk stratification and treatment guidance in HF.
  • Continued research into novel biomarkers is vital for improving patient outcomes and reducing healthcare costs associated with HF.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...